The Global Health Body Issues Concern Over Acute Lack of Obesity Injections

Under a tenth of patients who could benefit from GLP-1 drugs including Wegovy can access them, states the global health agency as it releases its initial guidance on the therapies.

With over a billion individuals worldwide currently living with obesity, it is calling for increased and just availability to this class of drugs.

According to estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.

"The new guidelines affirms that excess weight is a lifelong illness that can be treated with thorough and continuous care," stated its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and supply-chain constraints are major barriers to widespread availability to the injections that can aid individuals in losing substantial weight, says the organization.

Weight-Loss Drug Shortage

Despite the present most optimistic outlook, the supply of such drugs might only reach about 100 million people – less than 10% of those who need them, as stated by the WHO.

The advice calls on nations and manufacturers to widen availability, via approaches like patent sharing.

A patent on semaglutide – the primary component of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.

How Obesity Jabs Operate

GLP-1 drugs imitate a body's own hormone to delay gastric emptying, reduce hunger and increase the sense of being full so individuals eat less.

People usually begin shedding pounds within a few weeks of starting on the regular doses.

Evidence indicates users may put most of the weight back on within a year of halting the drug, when their usual hunger return.

Being carrying excess weight increases your risk for contracting diseases, like type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.

Excess weight impacts people in all nations and was linked to millions of fatalities worldwide in 2024, according to the WHO.